A clinical perspective on plasma cell leukemia; current status and future directions

Area of Science:

• Hematology
• Oncology

Background:

• Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a poor prognosis.
• The current diagnostic criteria for pPCL, based on peripheral blood plasma cell levels, are being challenged by data showing similar poor outcomes in patients with lower levels.

Purpose of the Study:

• To review the current understanding of primary plasma cell leukemia (pPCL) and its treatment landscape.
• To highlight the challenges in improving outcomes for pPCL patients and the need for further research.

Main Methods:

• Review of existing literature on primary plasma cell leukemia (pPCL).
• Analysis of current treatment strategies, including combination therapies, autologous hematopoietic cell transplantation, and emerging agents.
• Discussion of the rationale for using monoclonal antibodies and other novel therapies.

Main Results:

• Outcomes for pPCL patients have only modestly improved with novel therapies compared to multiple myeloma (MM).
• Secondary PCL arising from MM has a particularly poor outlook.
• Circulating plasma cells, even below diagnostic thresholds, are associated with an adverse prognosis.

Conclusions:

• Primary plasma cell leukemia (pPCL) remains a challenging diagnosis with limited therapeutic progress.
• Patients with pPCL should be considered for clinical trials to explore newer drug combinations, immunotherapy, and cellular therapies.
• Improving the prognosis of pPCL requires further investigation into novel treatment approaches.